Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives

References

• Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007. doi:10.1016/j.ejca.2015.06.110
   PubMed Web of Science ®Google Scholar
• Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–720. doi:10.1016/S1470-2045(08)70178-5
   PubMed Web of Science ®Google Scholar
• Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(4):419–428. doi:10.1001/jamadermatol.2015.4994
   PubMed Web of Science ®Google Scholar
• Soleymani T, Brodland DG, Arzeno J, Sharon DJ, Zitelli JA. Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs surgery alone: an analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death. J Am Acad Dermatol. 2023;88(1):109–117. doi:10.1016/j.jaad.2022.06.1169
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Libtayo (cemiplimab): EU public assessment report [homepage on the internet]; 2019. Available from: http://www.ema.europa.eu. Accessed March 16, 2023.
   Google Scholar
• Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. Epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60–82. doi:10.1016/j.ejca.2020.01.007
   PubMed Web of Science ®Google Scholar
• Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–3426. doi:10.1200/JCO.2010.34.1735
   PubMed Web of Science ®Google Scholar
• Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020;21(8):2956. doi:10.3390/ijms21082956
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals Inc. Libtayo (cemiplimab): US prescribing information [homepage on the internet]; 2019. Available from: http://www.regeneron.com. Accessed March 13, 2023.
   Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. doi:10.1056/NEJMoa1805131
   PubMed Web of Science ®Google Scholar
• NCI Dictionaries [homepage on the internet]. USA: RECIST; 2023. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/recist. Accessed March 16, 2023.
   Google Scholar
• Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, Phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294–305. doi:10.1016/S1470-2045(19)30728-4
   PubMed Web of Science ®Google Scholar
• Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9(8):e002757. doi:10.1136/jitc-2021-002757
   PubMed Web of Science ®Google Scholar
• Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1):e000775. doi:10.1136/jitc-2020-000775
   PubMed Web of Science ®Google Scholar
• Gross ND, Miller DM, Rischin D, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma. N Engl J Med. 2022;387(17):1557–1568. doi:10.1056/NEJMoa2209813
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Amit M, Nagarajan P, et al. Pilot Phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(16):4557–4565. doi:10.1158/1078-0432.CCR-21-0585
   PubMed Web of Science ®Google Scholar
• Pham F, Reynaud B, Favier B, Darnis S, Amini-Adle M. Cemiplimab removed from reimbursable drugs in France. Eur J Cancer. 2021;149:11–13. doi:10.1016/j.ejca.2021.02.041
   PubMed Web of Science ®Google Scholar
• Baggi A, Quaglino P, Rubatto M, et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer. 2021;157:250–258. doi:10.1016/j.ejca.2021.08.018
   PubMed Web of Science ®Google Scholar
• Challapalli A, Watkins S, Cogill G, et al. Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme. J Eur Acad Dermatol Venereol. 2022;36(7):e590–e592. doi:10.1111/jdv.18082
   PubMed Web of Science ®Google Scholar
• Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C. Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department. Br J Dermatol. 2021;185(5):1056–1058. doi:10.1111/bjd.20569
   PubMed Web of Science ®Google Scholar
• Hober C, Fredeau L, Pham-Ledard A, et al. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI Study Group. Cancers. 2021;13(14):3547. doi:10.3390/cancers13143547
   PubMed Web of Science ®Google Scholar
• Ríos-Viñuela E, Álvarez P, Lavernia J, et al. Cemiplimab in advanced cutaneous squamous cell carcinoma: real-world experience in a Monographic Oncology Center. Actas Dermosifiliogr. 2022;113(6):T610–T615. doi:10.1016/j.ad.2022.05.001
   PubMed Web of Science ®Google Scholar
• Strippoli S, Fanizzi A, Quaresmini D, et al. Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from Italy. Front Oncol. 2021;11:686308. doi:10.3389/fonc.2021.686308
   PubMed Web of Science ®Google Scholar
• Valentin J, Gérard E, Ferte T, et al. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J Geriatr Oncol. 2021;12(7):1110–1113. doi:10.1016/j.jgo.2021.02.026
   PubMed Web of Science ®Google Scholar
• Swanson L, Kassab I, Tsung I, Worden FP, Fontana RJ. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Immunotherapy. 2022;14(6):409–418. doi:10.2217/imt-2021-0191
   PubMed Web of Science ®Google Scholar
• Bailly-Caillé B, Kottler D, Morello R, et al. Real-life study of the benefit of concomitant radiotherapy with Cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC): a retrospective cohort study. Cancers. 2023;15(2):495. doi:10.3390/cancers15020495
   PubMed Web of Science ®Google Scholar
• Steren B, Burtness B, Bhatia A, et al. Cemiplimab for orbital squamous cell carcinoma in 11 cases. Ophthalmic Plast Reconstr Surg. 2022;38(5):496–502. doi:10.1097/IOP.0000000000002190
   PubMed Web of Science ®Google Scholar
• McLean LS, Lim AM, Webb A, et al. Immunotherapy to avoid orbital exenteration in patients with cutaneous squamous cell carcinoma. Front Oncol. 2022;11:796197. doi:10.3389/fonc.2021.796197
   PubMed Web of Science ®Google Scholar
• Goldfarb JA, Ferrarotto R, Gross N, et al. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2023;107(3):320–323. doi:10.1136/bjophthalmol-2021-319417
   PubMed Web of Science ®Google Scholar
• Wu MP, Reinshagen KL, Cunnane MB, et al. Clinical perineural invasion and immunotherapy for head and neck cutaneous squamous cell carcinoma. Laryngoscope. 2022;132(6):1213–1218. doi:10.1002/lary.29953
   PubMed Web of Science ®Google Scholar
• Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist. 2021;26(2):133–138. doi:10.1002/onco.13539
   PubMed Web of Science ®Google Scholar
• Saponara M, Pala L, Conforti F, et al. Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Ther Adv Med Oncol. 2020;12:1758835920977002. doi:10.1177/1758835920977002
   Web of Science ®Google Scholar
• Filippi L, Proietti I, Petrozza V, Bagni O, Schillaci O. Cutaneous squamous cell carcinoma subjected to anti PD-1 immunotherapy: monitoring response through serial PET/CT scans with 18F-FDG. Cancer Biother Radiopharm. 2022;37(3):226–232. doi:10.1089/cbr.2021.0368
   PubMed Web of Science ®Google Scholar
• McLean LS, Cavanagh K, Hicks RJ, et al. FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. Cancer Imaging. 2021;21(1):57. doi:10.1186/s40644-021-00426-2
   PubMed Web of Science ®Google Scholar
• Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296. doi:10.1001/jamadermatol.2016.4920
   PubMed Web of Science ®Google Scholar
• Ritter A, Badir S, Mansour M, et al. Solid organ transplantation worsens the prognosis of patients with cutaneous squamous cell carcinoma of the head and neck region- Comparison between solid organ transplant recipients and immunocompetent patients. Head Neck. 2021;43(3):884–894. doi:10.1002/hed.26546
   PubMed Web of Science ®Google Scholar
• Portuguese AJ, Tykodi SS, Blosser CD, Gooley TA, Thompson JA, Hall ET. Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review. J Natl Compr Canc Netw. 2022;20(4):406–416.e11. doi:10.6004/jnccn.2022.7009
   PubMed Web of Science ®Google Scholar
• Migden MR, Chandra S, Rabinowits G, et al. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020;16(4):11–19. doi:10.2217/fon-2019-0762
   PubMed Web of Science ®Google Scholar
• Study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT03969004. Accessed April, 2023.
   Google Scholar
• Neoadjuvant cemiplimab for the treatment of resectable NSCLC, HCC, and HNSCC. Available from: https://clinicaltrials.gov/ct2/show/NCT03916627. Accessed April, 2023.
   Google Scholar
• A PD-1 checkpoint inhibitor (Cemiplimab) for high-risk localized, locally recurrent, or regionally advanced skin cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT04315701. Accessed April, 2023.
   Google Scholar
• Cemiplimab before and after surgery for the treatment of high risk cutaneous squamous cell cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT4428671. Accessed April, 2023.
   Google Scholar
• Cemiplimab in AlloSCT/SOT recipients with CSCC (CONTRAC). Available from: https://clinicaltrials.gov/ct2/show/NCT04339062. Accessed March–April, 2023.
   Google Scholar